ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4299)	6/7/2016 7:34:52 AM
From: GregorioAllegri	Read Replies (1) of 4474

Since quite a number of patients with NSCLC have no known mutation driving their cancer, I would think Ariad and their cooperators would be very interested in finding out what unknown driver is responsible for the superscript "c" patients in the poster you linked (one PR and one SD) and would be working on it. My take away from yesterday: Camidge put forth a very simple model yesterday that, if it works out, bodes very well for the phase III brigatinib test: (1) Cancer inhibits DNA repair (2) Inhibiting DNA repair spawns ALK mutants (3) The compound that inhibits the most mutants has the longest lasting effect (4) the earlier the intervention the better the efficacy (even brigatinib does not control all mutants equally, so stopping the proliferation of mutants helps efficacy.) The race, as of now, in ALK is probably between alectinib and brigatinib. Apparently ceritinib already has a reputation for side effects. GA

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next